跳至主要内容
临床试验/NCT00455143
NCT00455143终止4 期

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Icahn School of Medicine at Mount Sinai1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
27
试验地点
1
主要终点
Functional Recovery

研究概览

简要总结

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

详细描述

Elderly patients who undergo anesthesia and non-cardiac surgery are subject to deterioration of brain function including the development of postoperative delirium (PD) and postoperative cognitive dysfunction (POCD). These disorders cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use relatively primitive approaches to preventing and treating PD and POCD. The proposed is a pilot study for an NIH grant which was recently submitted. This is a randomized controlled trial of perioperative dexmedetomidine to prevent PD and, potentially, POCD. Fifty patients will be enrolled at Mount Sinai with two different surgeries, either hip replacement or vascular bypass. The patients undergoing hip replacement will receive dexmedetomidine until discharge from the PACU. Vascular surgery patients who are transferred from the PACU to a monitored step-sown unit will continue dexmedetomidine for 24 hours.Participants will be screened for Mild Cognitive Impairment (MCI), and undergo preoperative cognitive testing. Unlike the parent trial, we will test for but will not select for patients with MCI. Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Follow up studies will include surveillance for delirium while in the hospital and cognitive testing at 3 months following surgery.

Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 65 years and older
  • elective major hip replacement or peripheral vascular (major surgery is defined by a planned 2 day hospitalization)
  • ASA physical status I-III
  • capable and willing to consent

排除标准

  • Cardiac surgery
  • Intracranial Surgery
  • Emergency Surgery
  • Patients with severe visual or auditory disorder/handicaps
  • Illiteracy
  • Patients with clinically significant Parkinson's Disease
  • Patients not expected to be able to complete the 3 month postoperative test
  • Sick sinus syndrome without pacemaker
  • Hypersensitivity to drug or class
  • Current 2nd or 3rd degree AV block
  • History of clinically significant bradycardia
  • Contraindication to the use of an 2A-agonist
  • Presence of a major psychiatric condition such as bipolar disorder, major depression, schizophrenia, or dementia
  • ASA physical status IV or V

研究组 & 干预措施

Dexmedetomidine

Experimental

Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.

干预措施: Precedex (Dexmedetomidine) (Drug)

Placebo

Placebo Comparator

Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.

干预措施: Placebo (Drug)

结局指标

主要结局

Functional Recovery

时间窗: 6 months post surgery

次要结局

  • Cognitive Testing(6 months post surgery)
  • Delirium Assessments(6 months post surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验